Bigul

Sun Pharmaceutical Industries Ltd - 524715 - Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30, 2021

The Board of Directors of the Company at its meeting held today i.e. July 30, 2021 has inter alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2021. Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we enclose herewith the following as 'Annexure': a) Unaudited (Standalone and Consolidated) Financial Results of the Company for the quarter ended June 30, 2021. b) Limited Review Report of the Statutory Auditors of the Company on Unaudited (Standalone and Consolidated) Financial Results for the quarter ended June 30, 2021. The meeting of the Board of Directors of the Company commenced at 10.15 a.m. and concluded at 1:45 p.m.
30-07-2021
Bigul

Sun Pharma, Cassiopea SpA ink license & supply agreements for acne treatment drug Winlevi

Sun Pharma will have the exclusive right to commercialise Winlevi in the United States and Canada, and Cassiopea will be the exclusive supplier of the product
26-07-2021
Bigul

Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release relating to the signing of license and supply agreements with Cassiopea SpA for Winlevi(r) Thanks
26-07-2021
Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Please find enclosed intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
25-07-2021
Bigul

Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Submission of Advertisement published in newspapers regarding Notice for transfer of equity shares and unclaimed dividend to the Investor Education and Protection Fund (IEPF) Account.
21-07-2021
Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Shareholding for the Period Ended June 30, 2021

Sun Pharmaceutical Industries Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here
20-07-2021

Stock Mantra: This largecap underperformer from pharma pack is set to challenge its 52-week high in 2 months

Sun Pharma has been in a long-term uptrend. The stock, unlike its peers, is moving steadily and giving periodic dips. This price action has led to the formation of a higher top, higher bottom structure, says Siddharth Bhamre of InCred Capital. Buy it in the Rs 685-695 range, for a target of Rs 810, he recommends.
19-07-2021
Bigul

Sun Pharmaceutical Industries Ltd - 524715 - Statement Of Investor Complaints For The Quarter Ended June 2021

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Ashok BhutaDesignation :- Any Other
17-07-2021
Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Statement Of Investor Complaints For The Quarter Ended June 2021

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Ashok BhutaDesignation :- Any Other
17-07-2021
Next Page
Close

Let's Open Free Demat Account